CA1062611A - Method of preparing a pharmaceutical composition for alleviation of uremic symptoms - Google Patents
Method of preparing a pharmaceutical composition for alleviation of uremic symptomsInfo
- Publication number
- CA1062611A CA1062611A CA222,929A CA222929A CA1062611A CA 1062611 A CA1062611 A CA 1062611A CA 222929 A CA222929 A CA 222929A CA 1062611 A CA1062611 A CA 1062611A
- Authority
- CA
- Canada
- Prior art keywords
- urea
- creatinine
- acid
- substrate
- creatine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 208000024891 symptom Diseases 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 129
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 84
- 239000004202 carbamide Substances 0.000 claims abstract description 74
- 229940109239 creatinine Drugs 0.000 claims abstract description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 42
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 40
- 244000005700 microbiome Species 0.000 claims abstract description 31
- 230000000593 degrading effect Effects 0.000 claims abstract description 30
- 239000000758 substrate Substances 0.000 claims abstract description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 21
- 230000001580 bacterial effect Effects 0.000 claims abstract description 20
- 229960003624 creatine Drugs 0.000 claims abstract description 20
- 239000006046 creatine Substances 0.000 claims abstract description 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 19
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940116269 uric acid Drugs 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 8
- 239000001963 growth medium Substances 0.000 claims abstract description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 8
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims abstract description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 6
- 241000894007 species Species 0.000 claims abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims abstract description 5
- 235000013343 vitamin Nutrition 0.000 claims abstract description 5
- 239000011782 vitamin Substances 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 5
- 239000012138 yeast extract Substances 0.000 claims abstract description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 4
- 235000000638 D-biotin Nutrition 0.000 claims abstract description 4
- 239000011665 D-biotin Substances 0.000 claims abstract description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 229960000304 folic acid Drugs 0.000 claims abstract description 4
- 235000019152 folic acid Nutrition 0.000 claims abstract description 4
- 239000011724 folic acid Substances 0.000 claims abstract description 4
- 239000011261 inert gas Substances 0.000 claims abstract description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 4
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 4
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 4
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 4
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 4
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 4
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 4
- 239000011677 pyridoxine Substances 0.000 claims abstract description 4
- 239000003381 stabilizer Substances 0.000 claims abstract description 4
- 235000019157 thiamine Nutrition 0.000 claims abstract description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960003495 thiamine Drugs 0.000 claims abstract description 4
- 239000011721 thiamine Substances 0.000 claims abstract description 4
- 229940045136 urea Drugs 0.000 claims abstract description 4
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 4
- 229960004050 aminobenzoic acid Drugs 0.000 claims abstract description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims abstract description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims abstract description 3
- 230000004151 fermentation Effects 0.000 claims abstract description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 241000589516 Pseudomonas Species 0.000 claims description 7
- 241000589158 Agrobacterium Species 0.000 claims description 5
- 241000589180 Rhizobium Species 0.000 claims description 5
- 241000607720 Serratia Species 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229910017464 nitrogen compound Inorganic materials 0.000 abstract description 51
- 150000002830 nitrogen compounds Chemical class 0.000 abstract description 17
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 239000002699 waste material Substances 0.000 abstract description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 3
- 244000000000 soil microbiome Species 0.000 description 43
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 34
- -1 NPN compounds Chemical class 0.000 description 34
- 241000894006 Bacteria Species 0.000 description 26
- 210000003734 kidney Anatomy 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 18
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 238000011282 treatment Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 239000002689 soil Substances 0.000 description 11
- 208000037157 Azotemia Diseases 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000009852 uremia Diseases 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 201000006370 kidney failure Diseases 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000004767 rumen Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 229960004198 guanidine Drugs 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000002747 voluntary effect Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000008953 bacterial degradation Effects 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000969130 Atthis Species 0.000 description 1
- 101100084503 Caenorhabditis elegans pas-3 gene Proteins 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000233732 Fusarium verticillioides Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000084978 Rena Species 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005735 Water intoxication Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N citral A Natural products CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000008664 renal activity Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- AYTGUZPQPXGYFS-UHFFFAOYSA-N urea nitrate Chemical compound NC(N)=O.O[N+]([O-])=O AYTGUZPQPXGYFS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2414156A DE2414156A1 (de) | 1974-03-23 | 1974-03-23 | Arzneimittel zur beseitigung uraemischer symptome und verfahren zu seiner herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1062611A true CA1062611A (en) | 1979-09-18 |
Family
ID=5911004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA222,929A Expired CA1062611A (en) | 1974-03-23 | 1975-03-24 | Method of preparing a pharmaceutical composition for alleviation of uremic symptoms |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4022883A (OSRAM) |
| BE (1) | BE826982A (OSRAM) |
| CA (1) | CA1062611A (OSRAM) |
| DE (1) | DE2414156A1 (OSRAM) |
| FR (1) | FR2264557B1 (OSRAM) |
| GB (1) | GB1488617A (OSRAM) |
| LU (1) | LU72106A1 (OSRAM) |
| NL (1) | NL7503426A (OSRAM) |
| SE (1) | SE7503260L (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706287B2 (en) | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| US7998470B2 (en) | 1999-04-30 | 2011-08-16 | Kibow Biotech, Inc. | Compositions and methods improving renal function |
| US11103542B2 (en) | 2002-03-13 | 2021-08-31 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
| US9980988B2 (en) * | 2002-03-13 | 2018-05-29 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
| US20050074442A1 (en) * | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
| AU2002255717B2 (en) * | 2002-03-13 | 2007-07-26 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
| US9655932B2 (en) | 2002-03-13 | 2017-05-23 | Kibow Biotech, Inc. | Composition and method for preventing or treating gout or hyperuricemia |
| AU2004277417B2 (en) * | 2003-09-30 | 2010-12-16 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
| US7198785B2 (en) * | 2003-12-09 | 2007-04-03 | Brown University | Systems and methods related to degradation of uremic toxins |
| JP5018478B2 (ja) * | 2005-07-08 | 2012-09-05 | 東レ株式会社 | 尿毒症改善のための治療剤および処置方法 |
| EP2057992B1 (en) * | 2006-08-21 | 2013-02-27 | Calpis Co., Ltd. | Renal-function-ameliorating agent |
| US11185562B2 (en) * | 2013-02-04 | 2021-11-30 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
| US11179426B2 (en) | 2016-12-29 | 2021-11-23 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3701830A (en) * | 1971-02-26 | 1972-10-31 | Monsanto Co | Method for improving oral health and hygiene in dogs and cats |
| JPS5226076B2 (OSRAM) * | 1972-10-06 | 1977-07-12 |
-
1974
- 1974-03-23 DE DE2414156A patent/DE2414156A1/de not_active Withdrawn
-
1975
- 1975-03-18 US US05/559,525 patent/US4022883A/en not_active Expired - Lifetime
- 1975-03-21 GB GB11989/75A patent/GB1488617A/en not_active Expired
- 1975-03-21 BE BE154585A patent/BE826982A/xx unknown
- 1975-03-21 NL NL7503426A patent/NL7503426A/xx not_active Application Discontinuation
- 1975-03-21 SE SE7503260A patent/SE7503260L/xx unknown
- 1975-03-21 FR FR7508848A patent/FR2264557B1/fr not_active Expired
- 1975-03-21 LU LU72106A patent/LU72106A1/xx unknown
- 1975-03-24 CA CA222,929A patent/CA1062611A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2414156A1 (de) | 1975-09-25 |
| BE826982A (fr) | 1975-07-16 |
| GB1488617A (en) | 1977-10-12 |
| SE7503260L (OSRAM) | 1975-09-24 |
| NL7503426A (nl) | 1975-09-25 |
| FR2264557B1 (OSRAM) | 1978-08-04 |
| US4022883A (en) | 1977-05-10 |
| FR2264557A1 (OSRAM) | 1975-10-17 |
| LU72106A1 (OSRAM) | 1975-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4314995A (en) | Pharmaceutical lactobacillus preparations | |
| US4871539A (en) | Biodeodorizer and process for preparing same | |
| Hawke et al. | Fish pasteurellosis of cultured striped bass (Morone saxatilis) in coastal Alabama | |
| US4022883A (en) | Composition for alleviation of uremic symptoms and method for its preparation | |
| JPH0413628A (ja) | クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物 | |
| CN114134083B (zh) | 一种贝莱斯芽孢杆菌及应用 | |
| JPH0779684B2 (ja) | ビフィズス菌増殖促進組成物 | |
| WO2007058027A1 (ja) | バチルス・チューリンゲンシスを含む有害菌の防除剤 | |
| Boyd et al. | Cerebrocortical necrosis in ruminants: An attempt to identify the source of thiaminase in affected animals | |
| EP0554319B1 (en) | Antimicrobial composition | |
| Gudev et al. | Effect of supplemental Sangrovit on some biochemical indices and leukocytes phagocytic activity in growing pigs | |
| RU2768281C1 (ru) | Комбинированный пробиотик для аквакультуры на основе спорообразующих бактерий рода bacillus и способ его производства | |
| RU2723411C2 (ru) | Штамм bacillus cereus rcam04578, продуцент биологически активных соединений, обладающий пробиотическими свойствами | |
| CN118749584A (zh) | 一种家禽用降尿酸的饲料添加剂及其组成的家禽饲料 | |
| US7998470B2 (en) | Compositions and methods improving renal function | |
| Hoogerheide | Antibiotic substances produced by soil bacteria | |
| RU2366448C2 (ru) | Способ получения препарата для лечения радиационных поражений организма животных и способ лечения радиационных поражений организма животных | |
| JP3180886B2 (ja) | 動物成長促進剤 | |
| RU2719676C1 (ru) | Способ улучшения обмена веществ у сельскохозяйственных животных с использованием микрокапсулированного интестевита | |
| US20110142924A1 (en) | Irilis biopreparation based on bacillus-strain bacteria, bacillus subtilis and bacillus licheniformis contained therein | |
| RU2401116C2 (ru) | Ранозаживляющий пробиотический препарат | |
| GB1585863A (en) | Pharmaceutical lactobacillus preparations | |
| JPH0838044A (ja) | ビフィズス菌増殖促進性及び生残性が良好なヨーグル ト | |
| KR100206454B1 (ko) | 신규한 락토바실러스 속 디에스-12균주와 이를 이용한 어류용 프로바이오틱스 | |
| RU2819889C1 (ru) | Способ получения кормовой композиции с функциональными свойствами для птицеводства |